Division of Lung Diseases, National Heart, Lung, and Blood Institute/ NIH, 6701 Rockledge Drive, Bethesda, MD 20892-7952, USA.
Am J Respir Crit Care Med. 2010 May 15;181(10):1121-7. doi: 10.1164/rccm.201001-0024WS. Epub 2010 Mar 11.
Mortality in National Heart, Lung and Blood Institute-sponsored clinical trials of treatments for acute lung injury (ALI) has decreased dramatically during the past two decades. As a consequence, design of such trials based on a mortality outcome requires ever-increasing numbers of patients. Recognizing that advances in clinical trial design might be applicable to these trials and might allow trials with fewer patients, the National Heart, Lung and Blood Institute convened a workshop of extramural experts from several disciplines. The workshop assessed the current state of clinical research addressing ALI, identified research needs, and recommended: (1) continued performance of trials evaluating treatments of patients with ALI; (2) development of strategies to perform ALI prevention trials; (3) observational studies of patients without ALI undergoing prolonged mechanical ventilation; and (4) development of a standardized format for reporting methods, endpoints, and results of ALI trials.
在过去的二十年中,美国国立心肺血液研究所(National Heart, Lung and Blood Institute)赞助的急性肺损伤(ALI)治疗临床试验中的死亡率显著下降。因此,基于死亡率结果设计此类试验需要越来越多的患者。鉴于临床试验设计的进展可能适用于这些试验,并可能允许使用更少的患者进行试验,美国国立心肺血液研究所召集了来自多个学科的外部专家研讨会。该研讨会评估了目前针对 ALI 的临床研究状况,确定了研究需求,并建议:(1)继续进行评估 ALI 患者治疗的试验;(2)制定策略开展 ALI 预防试验;(3)对接受长时间机械通气但无 ALI 的患者进行观察性研究;以及(4)制定报告 ALI 试验方法、终点和结果的标准化格式。